A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups

Vaccine

Volumn 29, Issue 49, 2011, Pages 9159-9170

  Michiels, Barbara ^a   Govaerts, Frans ^b   Remmen, Roy ^a   Vermeire, Etienne ^a   Coenen, Samuel ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b Prevention Commission   (Belgium)

Author keywords

Co morbidity; Effectiveness; Efficacy; Healthy; Inactivated vaccine; Influenza

Indexed keywords

INFLUENZA VACCINE;

ADULT; AGED; ASTHMA; BRONCHIECTASIS; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHILD; CHRONIC LUNG DISEASE; COMORBIDITY; CONTROLLED CLINICAL TRIAL (TOPIC); CYSTIC FIBROSIS; DIABETES MELLITUS; DISEASE DURATION; DRUG EFFICACY; FEVER; HEALTH CARE PERSONNEL; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INFECTION RISK; INFLUENZA; INFLUENZA VACCINATION; KIDNEY DISEASE; LABORATORY DIAGNOSIS; LIVER DISEASE; MORTALITY; NEWBORN; NONHUMAN; PNEUMONIA; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; VIRAL RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; COMORBIDITY; FEMALE; HEALTH PERSONNEL; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; PREGNANCY; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 80053413514     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.08.008     Document Type: Review

References (71)

1. World Health Organization. Recommended viruses for influenza vaccines for use in the 2010-2011 northern hemisphere influenza season: frequently asked questions. Geneva; 2010. p. 1-4. http://www.who.int/csr/disease/influenza/201002_RecommendationFAQ.pdf.
2. Jefferson T., Di Pietrantonj C., Rivetti A., Bawazeer G.A., Al-Ansary L.A., Ferroni E. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2010, (7). Art. No.: CD001269.
3. Nichol K.L. Efficacy and effectiveness of influenza vaccination. Vaccine 2008, 26S:D17-D22.
4. Couch R.B. Seasonal inactivated influenza virus vaccines. Vaccine 2008, 26S:D5-D9.
5. Hehme N.W., Künzel W., Petschke F., Türk G., Raderecht C., van Hoecke C., et al. Ten years of experience with the trivalent split-influenza vaccine, Fluarix. Clin Drug Invest 2002, 22(11):751-769.
6. Monto A.S. Seasonal influenza vaccinations: specialized products for different target groups. Vaccine 2010, 28(Suppl. 4):D14-D23.
7. Simonsen L., Viboud C., Taylor R.J., Miller M.A., Jackson Influenza vaccination and mortality benefits: new insights, new opportunities. Vaccine 2009, 27(45):6300-6304.
8. Nicoll A., Tsolova S. Guidance priority risk groups for influenza vaccination 2008, ECDC, Stockholm, http://ecdc.europa.eu/en/publications/Publications/0808_GUI_Priority_Risk_Groups_for_Influenza_Vaccination.pdf.
9. Fiore A.E., Uyeki T.M., Broder K., Finelli L., Euler G.L., Singleton J.A., et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010, 59(RR-8):1-62.
10. Comité voor de Evaluatie van de Medische Praktijk inzake Geneesmiddelen (CEG)[[nl]]Committee for the evaluation of medical practice Doelmatig gebruik van medische interventies bij de aanpak van influenza in de ambulante sector 2010, Rijksinstituut voor Ziekte- en Invaliditeitsverzekering[[nl]]National Institute for Health and Disability Insurance, Brussel, p. 1-107. http://www.riziv.fgov.be/drug/nl/statistics-scientific-information/consensus/index.htm.
11. Shea B.J., Hamel C., Wells G.A., Bouter L.M., Kristjansson E., Grimshaw J., et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol 2009, 62(10):1013-1020.
12. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.0.2 [updated September 2009]. The Cochrane Collaboration: ; 2009. http://www.cochrane-handbook.org/.
13. Atkins D., Best D., Briss P.A., Eccles M., Falck-Ytter Y., Flottorp S., et al. Grading quality of evidence and strength of recommendations. BMJ 2004, 328(7454):1490-1497.
14. Guyatt G.H., Oxman A.D., Vist G.E., Kunz R., Falck-Ytter Y., Alonso-Coello P., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008, 336:924.
15. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009, 339:b2535. PRISMA Group.
16. Jadad A., Moore R.A., Carroll D., Jenkinson C., Reynolds J.M., Gavaghan D.J., et al. Assessing the quality of reports of randomised controlled trials: is blinding necessary?. Controlled Clin Trials 1996, 17(1-12).
17. Thomas R.E., Jefferson T., Lasserson T.J. Influenza vaccination for healthcare workers who work with the elderly. Cochrane Database Syst Rev 2010, (2). Art. No.: CD005187.
18. Cheuk D.K.L., Chiang A.K.S., Lee T.L., Chan G.C.F., Ha S.Y. Vaccines for prophylaxis of viral infections in patients with hematological malignancies. Cochrane Database Syst Rev 2011, (3). Art. No.: CD006505. 10.1002/14651858.CD006505.pub2.
19. Anema A., Mills E., Montaner J., Brownstein J.S., Cooper C. Efficacy of influenza vaccination in HIV-positive patients: a systematic review and meta-analysis. HIV Med 2008, 9(1):57-61.
20. Monto A.S., Ohmit S.E., Petrie J.G., Johnson E., Truscon R., Teich E., et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009, 361(13):1260-1267.
21. Ohmit S.E., Victor J.C., Rotthoff J.R., Teich E.R., Truscon R.K., Baum L.L., et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 2006, 355(24):2513-2522.
22. Ohmit S.E., Victor J.C., Teich E.R., Truscon R.K., Rotthoff J.R., Newton D.W., et al. Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines. J Infect Dis 2008, 198(3):312-317.
23. Madhi S.A., Maskew M., Koen A., Kuwanda L., Besselaar T.G., Naidoo D., et al. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis 2011, 52(1):128-137.
24. Jansen A.G., Sanders E.A., Hoes A.W., van Loon A.M., Hak E. Effects of influenza plus pneumococcal conjugate vaccination versus influenza vaccination alone in preventing respiratory tract infections in children: a randomized, double-blind, placebo-controlled trial. J Pediatr 2008, 153(6):764-770.
25. Zaman K., Roy E., Arifeen S.E., Rahman M., Raqib R., Wilson E., et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008, 359(15):1555-1564.
26. Barrett P.N., Berezuk G., Fritsch S., Aichinger G., Hart M.K., El-Amin W., et al. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2011, 377(9767):751-759.
27. Frey S., Vesikari T., Szymczakiewicz-Multanowska A., Lattanzi M., Izu A., Groth N., et al. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis 2010, 51(9):997-1004.
28. Jackson L.A., Gaglani M.J., Keyserling H.L., Balser J., Bouveret N., Fries L., et al. Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons. BMC Infect Dis 2010, 10:71.
29. Loeb M., Russell M.L., Moss L., Fonseca K., Fox J., Earn D.J., et al. Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. JAMA 2010, 303(10):943-950.
30. Hui L.S., Rashwan H., bin Jaafar M.H., Hussaini H.M., Isahak D.I. Effectiveness of influenza vaccine in preventing influenza-like illness among Faculty of Dentistry staff and students in University Kebangsaan Malaysia. Healthc Infect 2008, 13(1):4-9.
31. Marchisio P., Esposito S., Bianchini S., Dusi E., Fusi M., Nazzari E., et al. Efficacy of injectable trivalent virosomal-adjuvanted inactivated influenza vaccine in preventing acute otitis media in children with recurrent complicated or noncomplicated acute otitis media. Pediatr Infect Dis J 2009, 28(10):855-859.
32. Phrommintikul A., Kuanprasert S., Wongcharoen W., Kanjanavanit R., Chaiwarith R., Sukonthasarn A. Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome. Eur Heart J 2011.
33. Song J.Y., Cheong H.J., Ha S.H., Hwang I.S., Kee S.Y., Jeong H.W., et al. Clinical impact of influenza immunization in patients with liver cirrhosis. J Clin Virol 2007, 39(3):159-163.
34. Anar C., Bicmen C., Yapicioglu S., Unsal I., Halilcolar H., Yilmaz U. Evaluation of clinical data and antibody response following influenza vaccination in patients with chronic obstructive pulmonary disease. New Microbiol 2010, 33(2):117-127.
35. Michiels B., Philips H., Coenen S., Yane F., Steinhauser T., Stuyck S., et al. The effect of giving influenza vaccination to general practitioners: a controlled trial [NCT00221676]. BMC Med 2006, 4:17.
36. Ochiai H., Fujieda M., Ohfuji S., Fukushima W., Kondo K., Maeda A., et al. Inactivated influenza vaccine effectiveness against influenza-like illness among young children in Japan--with special reference to minimizing outcome misclassification. Vaccine 2009, 27(50):7031-7035.
37. Jefferson T., Rivetti A., Harnden A., Di Pietrantonj C., Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2008, (2). Art. No.: CD004879.
38. Jefferson T., Di Pietrantonj C., Al-Ansary L.A., Ferroni E., Thorning S., Thomas R.E. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2010, 2:CD004876.
39. Poole P.J., Chacko E., Wood-Baker R.W., Cates C.J. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006, (1). CD002733.
40. Cates C.J., Jefferson T.O., Rowe B.H. Vaccines for preventing influenza in people with asthma. Cochrane Database Syst Rev 2008, (2). CD000364.
41. Chang C.C., Morris P.S., Chang A.B. Influenza vaccine for children and adults with bronchiectasis. Cochrane Database Syst Rev 2007, (3). CD006218.
42. Dharmaraj P., Smyth R.L. Vaccines for preventing influenza in people with cystic fibrosis. Cochrane Database Syst Rev 2009, (4):CD001753.
43. Keller T., Weeda V.B., van Dongen C.J., Levi M. Influenza vaccines for preventing coronary heart disease. Cochrane Database Syst Rev 2008, (3). CD005050.
44. Goossen G.M., Kremer L.C.M., van de Wetering M.D. Influenza vaccination in children being treated with chemotherapy for cancer. Cochrane Database Syst Rev 2009, (2). Art. No.: CD006484.
45. van der Wouden J., Bueving H., Poole P. Preventing influenza: an overview of systematic reviews. Respir Med 2005, 99(11):1341-1349.
46. Ambrose C.S., Wu X., Belshe R.B. The efficacy of live attenuated and inactivated influenza vaccines in children as a function of time postvaccination. Pediatr Infect Dis J 2010, 29(9):806-811.
47. Seidman J.C., Richard S.A., Viboud C., Miller M.A. Quantitative review of antibody response to inactivated seasonal influenza vaccines. Influenza Other Respir Viruses 2011, 10.1111/j.750-2659.011.00268.x.
48. Belshe R.B., Edwards K.M., Vesikari T., Black S.V., Walker R.E., Hultquist M., et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007, 356(7):685-696.
49. Vesikari T., Pellegrini M., Karvonen A., Groth N., Borkowski A., O'Hagan D.T., et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009, 28(7):563-571.
50. Glezen W.P., Simonsen L. Commentary: benefits of influenza vaccine in US elderly-new studies raise questions. Int J Epidemiol 2006, 35:352-353.
51. Simonsen L., Reichert T.A., Viboud C., Blackwelder W.C., Taylor R.J., MA M. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med 2005, 165(3):265-272.
52. Eurich D.T., Marrie T.J., Johnstone J., Majumdar S.R. Mortality reduction with influenza vaccine in patients with pneumonia outside flu season: pleiotropic benefits or residual confounding?. Am J Respir Crit Care Med (United States) 2008, 178(5):527-533.
53. Jackson L.A., Jackson M.L., Nelson J.C., Neuzil K.M., Weiss N.S. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol 2006, 35(2):337-344.
54. Nichol K.L., Nordin J.D., Nelson D.B., Mullooly J.P., Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 2007, 357(14):1373-1381.
55. Hak E., Hoes A.W., Nordin J., Nichol K.L. Benefits of influenza vaccine in US elderly - appreciating issues of confounding bias and precision. Int J Epidemiol 2006, 35(3):800-802.
56. Simonsen L., Taylor R.J., Viboud C., Miller M.A., Jackson L.A. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis 2007, 7(10):658-666.
57. Baxter R., Lee J., Fireman B. Evidence of bias in studies of influenza vaccine effectiveness in elderly patients. J Infect Dis 2010, 201(2):186-189.
58. Xing Y., Liu M. Meta analysis on the effectiveness of inactivated influenza vaccine. Zhonghua Liu Xing Bing Xue Za Zhi 2009, 30(4):368-370.
59. Petrie J.G., Ohmit S.E., Johnson E., Cross R.T., Monto A.S. Efficacy studies of influenza vaccines: effect of end points used and characteristics of vaccine failures. J Infect Dis 2011, 203(9):1309-1315.
60. Hoge gezondheidsraad [High Council of Health]. Vaccinatie tegen seizoensgebonden griep Winterseizoen 2010-2011 [Vaccination against seasonal influenza - season 2010-2011], vol. 8682. Brussel; 2010. http://www.zorg-en-gezondheid.be/griep.aspx%23TOP.
61. World Health Organization Influenza vaccines: recommendations for the use of inactivated influenza vaccines and other preventive measures. Weekly Epidemiol Rec 2000, 75(35):281-288.
62. Fireman B., Lee J., Lewis N., Bembom O., van der Laan M., Baxter R. Influenza vaccination and mortality: differentiating vaccine effects from bias. Am J Epidemiol 2009, 170(5):650-656.
63. Baxter R., Ray G.T., Fireman B.H. Effect of influenza vaccination on hospitalizations in persons aged 50 years and older. Vaccine 2010, 28(45):7267-7272.
64. Jackson M.L., Nelson J.C., Weiss N.S., Neuzil K.M., Barlow W., Jackson L.A. Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: a population-based, nested case-control study. Lancet 2008, 372(9636):398-405.
65. Scuffham P.A., West P.A. Economic evaluation of strategies for the control and management of influenza in Europe. Vaccine 2002, 20(19-20):2562-2578.
66. Guyatt G., Oxman A.D., Akl E.A., Kunz R., Vist G., Brozek J., et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011, 64(4):383-394.
67. Guyatt G.H., Oxman A.D., Kunz R., Falck-Ytter Y., Vist G.E., Liberati A., et al. Going from evidence to recommendations. BMJ 2008, 336(7652):1049-1051.
68. Newall A.T., Kelly H., Harsley S., Scuffham P.A. Cost effectiveness of influenza vaccination in older adults: a critical review of economic evaluations for the 50- to 64-year age group. Pharmacoeconomics 2009, 27(6):439-450.
69. Brożek J.L., Akl E.A., Compalati E., Kreis J., Terracciano L., Fiocchi A., et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines part 3 of 3. The GRADE approach to developing recommendations. Allergy 2011, 66(5):588-595.
70. Rimmelzwaam G.F., Mc Elhaney J.E. Correlates of protection: novel generations of influenza vaccines. Vaccine 2008, 26S:D41-D44.
71. Thomas R.E., Jefferson T., Lasserson T.J. Influenza vaccination for healthcare workers who work with the elderly: systematic review. Vaccine 2010, 29(2):344-356.